Use of dupilumab to manage a grade 3 cutaneous adverse effect from enfortumab vedotin/pembrolizumab treatment in a patient with metastatic urothelial carcinoma

Use of dupilumab to manage a grade 3 cutaneous adverse effect from enfortumab vedotin/pembrolizumab treatment in a patient with metastatic urothelial carcinoma

Saved in:
Bibliographic Details
Main Authors: Maura C. Gillis, BA, Vanessa R. Weir, BA, Cecilia Lezcano, MD, Gopa Iyer, MD, Allison Gordon, MD
Format: Article
Language:English
Published: Elsevier 2025-02-01
Series:JAAD Case Reports
Subjects:
bullous
dupilumab
enfortumab vedotin
flexural
oncodermatology
pembrolizumab
Online Access:http://www.sciencedirect.com/science/article/pii/S235251262400417X
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items